VICP实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (1 May 2024 @ 22:31):

Stats
今日成交量	1 245.00
平均成交量	81.00
市值	31.75M
EPS	$-0.00699 ( 2023-09-29 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-33.00
ATR14	$0 (0.00%)

Insider Trading

Date	Person	Action	Amount	type
2010-09-03	Yurkowski Michael	Sell	5 000	SSGI
2010-08-09	Yurkowski Michael	Sell	20 000	Common Stock
2010-05-13	Moore Bobby M Jr	Sell	0	Common Stock
2010-01-26	Yurkowski Michael	Sell	5 000	SSGI
2010-01-14	Yurkowski Michael	Sell	5 000	Common Stock

INSIDER POWER
0.00
Last 19 transactions
Buy: 0 \| Sell: 1 754 181

Vicapsys Life Sciences, 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Vicapsys Life Sciences, 财务报表

Annual	2022
营收:	$0
毛利润:	$-31 288.00 (0.00 %)
EPS:	$-0.0545

FY	2022
营收:	$0
毛利润:	$-31 288.00 (0.00 %)
EPS:	$-0.0545

FY	2021
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$-0.0100

FY	2020
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$-0.100

Financial Reports:

No articles found.

Vicapsys Life Sciences,

Vicapsys Life Sciences, Inc. focuses on the development and commercialization of VICAPSYN proprietary product. Its product is applied to transplantation therapies and related stem-cell applications in the transplantation field. The company is also developing VYBRIN, a product based on CXCL12 for prevention of post-surgical adhesions in abdominal surgery, coating of implantable medical devices and other implants to eliminate fibrosis, and wound healing with a focus on diabetic ulcers. The company was formerly known as Phage Therapeutics International, Inc. and changed its name to Vicapsys Life Sciences, Inc. in September 2017. Vicapsys Life Sciences, Inc. was incorporated in 1997 and is based in Suwanee, Georgia.